311 related articles for article (PubMed ID: 26273932)
21. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
22. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
[TBL] [Abstract][Full Text] [Related]
23. Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival.
Dixon SC; Ibiebele TI; Protani MM; Beesley J; deFazio A; Crandon AJ; Gard GB; Rome RM; Webb PM; Nagle CM;
Gynecol Oncol; 2014 Mar; 132(3):566-72. PubMed ID: 24368279
[TBL] [Abstract][Full Text] [Related]
24. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
[TBL] [Abstract][Full Text] [Related]
25. Socioeconomic status and epithelial ovarian cancer survival in Sweden.
Weiderpass E; Oh JK; Algeri S; Bellocco R
Cancer Causes Control; 2014 Aug; 25(8):1063-73. PubMed ID: 24906473
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.
Lundgren S; Berntsson J; Nodin B; Micke P; Jirström K
J Ovarian Res; 2016 Apr; 9():21. PubMed ID: 27048364
[TBL] [Abstract][Full Text] [Related]
28. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
[TBL] [Abstract][Full Text] [Related]
29. Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer.
Ataseven B; du Bois A; Harter P; Prader S; Grimm C; Kurzeder C; Schneider S; Heikaus S; Kahl A; Traut A; Heitz F
Int J Gynecol Cancer; 2016 Nov; 26(9):1594-1600. PubMed ID: 27654263
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
31. Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition.
Ose J; Fortner RT; Rinaldi S; Schock H; Overvad K; Tjonneland A; Hansen L; Dossus L; Fournier A; Baglietto L; Romieu I; Kuhn E; Boeing H; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Masala G; Sieri S; Tumino R; Sacerdote C; Mattiello A; Ramon Quiros J; Obón-Santacana M; Larrañaga N; Chirlaque MD; Sánchez MJ; Barricarte A; Peeters PH; Bueno-de-Mesquita HB; Onland-Moret NC; Brändstedt J; Lundin E; Idahl A; Weiderpass E; Gram IT; Lund E; Kaw KT; Travis RC; Merritt MA; Gunther MJ; Riboli E; Kaaks R
Int J Cancer; 2015 Jan; 136(2):399-410. PubMed ID: 24890047
[TBL] [Abstract][Full Text] [Related]
32. Comparison Of Early-Stage High-Grade Serous Primary Fallopian Tube Cancers and Epithelial Ovarian Cancers: A Multicenter Study.
Gungorduk K; Ozdemir A; Selcuk I; Telli E; Şahin Ö; Toptaş T; Akman L; Güzel AB; Taşkın S; Öge T; Güngördük Ö; Gokçü M; Gungor T; Yaşar L; Terek MC; Ozan H; Ozsaran A; Sancı M; Vardar MA; Meydanlı MM; Yalçın ÖT; Ortac F; Özalp S
Oncol Res Treat; 2017; 40(4):203-206. PubMed ID: 28376498
[TBL] [Abstract][Full Text] [Related]
33. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
[TBL] [Abstract][Full Text] [Related]
34. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK
Cancer; 2017 May; 123(6):977-984. PubMed ID: 28263384
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract][Full Text] [Related]
36. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Vogel TJ; Goodman MT; Li AJ; Jeon CY
Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
[TBL] [Abstract][Full Text] [Related]
37. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
Dahm-Kähler P; Borgfeldt C; Holmberg E; Staf C; Falconer H; Bjurberg M; Kjölhede P; Rosenberg P; Stålberg K; Högberg T; Åvall-Lundqvist E
Gynecol Oncol; 2017 Jan; 144(1):167-173. PubMed ID: 27817932
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO.
Klar M; Hasenburg A; Hasanov M; Hilpert F; Meier W; Pfisterer J; Pujade-Lauraine E; Herrstedt J; Reuss A; du Bois A
Eur J Cancer; 2016 Oct; 66():114-24. PubMed ID: 27561452
[TBL] [Abstract][Full Text] [Related]
39. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.
Kumar A; Langstraat CL; DeJong SR; McGree ME; Bakkum-Gamez JN; Weaver AL; LeBrasseur NK; Cliby WA
Gynecol Oncol; 2017 Oct; 147(1):104-109. PubMed ID: 28734497
[TBL] [Abstract][Full Text] [Related]
40. Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women.
McGuire V; Hartge P; Liao LM; Sinha R; Bernstein L; Canchola AJ; Anderson GL; Stefanick ML; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1059-63. PubMed ID: 27197274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
